1. ALLA AKTIER
  2. NYHETER
  3. LIDDS

LIDDS

Nyheter LIDDS Nyheter alla bolag

LIDDS moves the publication of the Annual Report 2023 forward

MARKN.

The board of LIDDS AB (publ) has decided to move forward the Annual General Meeting of shareholders 2024 and the publication of the Annual report for 2023. The Annual General Meeting will be held on 27 May 2024 and publication of the Annual report for 2023 will be made on 6 May 2024.

Previous dates for publication of the Annual report for 2023 were 23 April 2024 and the Annual General Meeting 15 May 2024. The move is made primarily to be able to include more information about the acquisition of Noviga Research AB.

For additional information, please contact

Jenni Björnulfson, CEO and CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS’ Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. LIDDS offers the NanoZolid technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. The company is listed on Nasdaq First North Growth market.

Attachments

LIDDS moves the publication of the Annual Report 2023 forward

Datum 2024-04-17, kl 11:50
Källa MFN
Bifogade filer
LIDDS moves the publication of the Annual Report 2023 forward
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!